Abstract
Background: The coronavirus disease-2019 (COVID-19) is a systemic disease with severe implications on the vascular and coagulation system. A procoagulant platelet phenotype has been reported at least in the acute disease phase. Soluble P-selectin (sP-sel) in the plasma is a surrogate biomarker of platelet activation. Increased plasma levels of sP-sel have been reported in hospitalized COVID-19 patients associated with disease severity. Here, we evaluated in a longitudinal study the sP-sel plasma concentration in blood donors who previously suffered from moderate COVID-19.
Methods: 154 COVID-19 convalescent and 111 non-infected control donors were recruited for plasma donation and for participation in the CORE research trial. First donation (T1) was performed 43-378 days after COVID-19 diagnosis. From most of the donors the second (T2) plasma donation including blood sampling was obtained after a time period of 21-74 days and the third (T3) donation after additional 22-78 days. Baseline characteristics including COVID-19 symptoms of the donors were recorded based on a questionnaire. Platelet function was measured at T1 by flow cytometry and light transmission aggregometry in a representative subgroup of 25 COVID-19 convalescent and 28 control donors. The sP-sel plasma concentration was determined in a total of 704 samples by using a commercial ELISA.
Results: In vitro platelet function was comparable in COVID-19 convalescent and control donors at T1. Plasma samples from COVID-19 convalescent donors revealed a significantly higher sP-sel level compared to controls at T1 (1.05 ± 0.42 ng/mL vs. 0.81 ± 0.30 ng/mL; p < 0.0001) and T2 (0.96 ± 0.39 ng/mL vs. 0.83 ± 0.38 ng/mL; p = 0.0098). At T3 the sP-sel plasma level was comparable in both study groups. Most of the COVID-19 convalescent donors showed a continuous decrease of sP-sel from T1 to T3.
Conclusion: Increased sP-sel plasma concentration as a marker for platelet or endothelial activation could be demonstrated even weeks after moderate COVID-19, whereas, in vitro platelet function was comparable with non-infected controls. We conclude that COVID-19 and additional individual factors could lead to an increase of the sP-sel plasma level.
Keywords: CD62P; COVID-19; Plasma marker; Platelet function; SARS-CoV-2 infection; Soluble P-selectin.
【저자키워드】 COVID-19, SARS-COV-2 infection, CD62P, Plasma marker, Platelet function, Soluble P-selectin., 【초록키워드】 coronavirus disease, SARS-CoV-2, platelet activation, coronavirus, Biomarker, Trial, SARS-COV-2 infection, disease severity, Transmission, in vitro, flow cytometry, ELISA, Moderate COVID-19, P-selectin, coronavirus disease-2019, Coagulation, Blood donors, Participation, Characteristics, longitudinal study, Research, COVID-19 diagnosis, Control, Platelet, phenotype, plasma, Coagulation system, donors, convalescent, disease, COVID-19 symptoms, questionnaire, Blood, Donor, hospitalized COVID-19 patient, CD62P, marker, systemic disease, blood donor, COVID-19 symptom, lead, acute disease, plasma concentration, endothelial, Activation, Factor, Vascular, hospitalized COVID-19 patients, baseline characteristics, plasma samples, study groups, blood sampling, MOST, COVID-19 convalescent donors, implication, controls, decrease, procoagulant, non-infected, was measured, recruited, reported, evaluated, was performed, was determined, demonstrated, suffered, significantly higher, comparable, Increased, was obtained, were recorded, COVID-19 convalescent donor, 【제목키워드】 P-selectin, Increased, COVID-19 convalescent donor,